HIGHLIGHTS
- who: Rui Zhao and colleagues from the Guizhou Medical University, Guiyang, Guizhou, China have published the Article: NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway, in the Journal: (JOURNAL)
- what: The research shows that NAP1L5 is expressed at low levels in HCC and that its expression is related to the survival rate of patients, further proving that NAP1L5 regulates MYH9 to inhibit the progression of HCC through the PI3K/AKT/mTOR signaling pathway.
- how: The authors performed a pathological analysis of the lung tissue of nude mice . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.